Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: assets

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash and cash equivalents	4,569,600)	10,369,100)	10,504,000)	6,795,000)	5,988,187)
Marketable securities	1,546,300)	849,200)	274,500)	729,900)	670,710)
Accounts receivable, net	1,609,400)	1,563,400)	1,442,200)	1,136,800)	885,352)
Inventories	1,205,400)	738,800)	460,600)	353,100)	280,777)
Tax-related prepaid and receivables	357,000)	429,000)	319,800)	358,600)	228,600)
Prepaid expenses	102,200)	108,600)	111,800)	83,500)	—)
Fair value of cash flow hedges	130,100)	1,800)	47,500)	44,500)	—)
Other	76,400)	84,300)	74,400)	59,200)	79,753)
Prepaid expenses and other current assets	665,700)	623,700)	553,500)	545,800)	308,353)
Current assets	9,596,400)	14,144,200)	13,234,800)	9,560,600)	8,133,379)
Property and equipment, net	1,227,800)	1,159,300)	1,108,400)	1,094,100)	958,534)
Goodwill	1,088,000)	1,088,000)	1,088,000)	1,002,200)	1,002,158)
Other intangible assets, net	825,900)	839,900)	603,600)	400,000)	400,000)
Deferred tax assets	2,331,100)	1,812,100)	1,246,900)	934,500)	882,779)
Operating lease assets	1,356,800)	293,600)	347,400)	330,300)	325,564)
Long-term marketable securities	5,107,900)	2,497,800)	112,200)	—)	—)
Other assets	999,300)	895,300)	409,600)	110,800)	49,394)
Non-current assets	12,936,800)	8,586,000)	4,916,100)	3,871,900)	3,618,429)
Total assets	22,533,200)	22,730,200)	18,150,900)	13,432,500)	11,751,808)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Vertex Pharmaceuticals Inc. current assets increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Property and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Vertex Pharmaceuticals Inc. property and equipment, net increased from 2022 to 2023 and from 2023 to 2024.
Non-current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Vertex Pharmaceuticals Inc. non-current assets increased from 2022 to 2023 and from 2023 to 2024.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Vertex Pharmaceuticals Inc. total assets increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Vertex Pharmaceuticals Inc. cash and cash equivalents decreased from 2022 to 2023 and from 2023 to 2024.
Marketable securities	Amount of investment in marketable security, classified as current.	Vertex Pharmaceuticals Inc. marketable securities increased from 2022 to 2023 and from 2023 to 2024.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Vertex Pharmaceuticals Inc. accounts receivable, net increased from 2022 to 2023 and from 2023 to 2024.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Vertex Pharmaceuticals Inc. inventories increased from 2022 to 2023 and from 2023 to 2024.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items